Can Little Novavax Beat Its Big Coronavirus Vaccine Rivals?
It's not surprising that several of the biggest drugmakers in the world have emerged as leaders in the race to develop a coronavirus vaccine. After all, they have vast resources. Some developed their own COVID-19 vaccine candidates, while others used their money to team up with other organizations that had promising programs.
Novavax (NASDAQ: NVAX) stands as a clear outlier. At the beginning of 2020, the biotech's market cap was below $130 million. Even after a remarkable share price surge so far this year, Novavax remains only a fraction of the size of other drugmakers with leading coronavirus vaccine candidates.
But could little Novavax really beat its much bigger rivals in the coronavirus vaccine race?
Source Fool.com
